145 related articles for article (PubMed ID: 1429095)
41. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation.
Gulati S; Yahalom J; Acaba L; Reich L; Motzer R; Crown J; Toia M; Igarashi T; Lemoli R; Hanninen E
J Clin Oncol; 1992 Jun; 10(6):936-41. PubMed ID: 1588372
[TBL] [Abstract][Full Text] [Related]
42. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W
Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
[TBL] [Abstract][Full Text] [Related]
43. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis.
Takvorian T; Canellos GP; Ritz J; Freedman AS; Anderson KC; Mauch P; Tarbell N; Coral F; Daley H; Yeap B
N Engl J Med; 1987 Jun; 316(24):1499-505. PubMed ID: 3295542
[TBL] [Abstract][Full Text] [Related]
44. The clinical value of follow-up examinations in childhood T-cell acute lymphoblastic leukemia and T-cell non-Hodgkin's lymphoma.
Huang L; Lequin M; Pieters R; van den Heuvel-Eibrink MM
Pediatr Blood Cancer; 2007 Apr; 48(4):468-72. PubMed ID: 16514610
[TBL] [Abstract][Full Text] [Related]
45. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse.
Freedman AS; Takvorian T; Anderson KC; Mauch P; Rabinowe SN; Blake K; Yeap B; Soiffer R; Coral F; Heflin L
J Clin Oncol; 1990 May; 8(5):784-91. PubMed ID: 2332768
[TBL] [Abstract][Full Text] [Related]
46. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study.
Freedman AS; Takvorian T; Neuberg D; Mauch P; Rabinowe SN; Anderson KC; Soiffer RJ; Spector N; Grossbard M; Robertson MJ
J Clin Oncol; 1993 May; 11(5):931-6. PubMed ID: 8487057
[TBL] [Abstract][Full Text] [Related]
47. Sensitivity of primary clonogenic blasts from acute lymphoblastic leukemia patients to an activated cyclophosphamide, viz., mafosfamide.
Uckun FM; Chandan-Langlie M; Dockham PA; Aeppli D; Sladek NE
Leuk Lymphoma; 1994 May; 13(5-6):417-28. PubMed ID: 8069187
[TBL] [Abstract][Full Text] [Related]
48. Time-dependent effect of non-Hodgkin's lymphoma grade on disease-free survival of relapsed/refractory patients treated with high-dose chemotherapy plus autotransplantation.
Fu P; van Heeckeren WJ; Wadhwa PD; Bajor DJ; Creger RJ; Xu Z; Cooper BW; Laughlin MJ; Gerson SL; Koç ON; Lazarus HM
Contemp Clin Trials; 2008 Mar; 29(2):157-64. PubMed ID: 17707140
[TBL] [Abstract][Full Text] [Related]
49. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Sociét Française de Greffe de Moelle.
Dhedin N; Giraudier S; Gaulard P; Esperou H; Ifrah N; Michallet M; Milpied N; Rio B; Cahn JY; Molina L; Laporte JL; Guilhot F; Kuentz M
Br J Haematol; 1999 Oct; 107(1):154-61. PubMed ID: 10520036
[TBL] [Abstract][Full Text] [Related]
50. Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia.
Aversa F; Terenzi A; Carotti A; Felicini R; Jacucci R; Zei T; Latini P; Aristei C; Santucci A; Martelli MP; Cunningham I; Reisner Y; Martelli MF
J Clin Oncol; 1999 May; 17(5):1545-50. PubMed ID: 10334542
[TBL] [Abstract][Full Text] [Related]
51. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
Lazarus HM; Loberiza FR; Zhang MJ; Armitage JO; Ballen KK; Bashey A; Bolwell BJ; Burns LJ; Freytes CO; Gale RP; Gibson J; Herzig RH; LeMaistre CF; Marks D; Mason J; Miller AM; Milone GA; Pavlovsky S; Reece DE; Rizzo JD; van Besien K; Vose JM; Horowitz MM
Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
[TBL] [Abstract][Full Text] [Related]
52. Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors.
Lundberg JH; Hansen RM; Chitambar CR; Lawton CA; Gottlieb M; Anderson T; Ash RC
J Clin Oncol; 1991 Oct; 9(10):1848-59. PubMed ID: 1919635
[TBL] [Abstract][Full Text] [Related]
53. Total body irradiation prior to bone marrow transplantation: efficacy and safety of granisetron in the prophylaxis and control of radiation-induced emesis.
Belkacémi Y; Ozsahin M; Pène F; Rio B; Sutton L; Laporte JP; Touboul E; Gorin NC; Laugier A
Int J Radiat Oncol Biol Phys; 1996 Aug; 36(1):77-82. PubMed ID: 8823261
[TBL] [Abstract][Full Text] [Related]
54. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM
Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
[TBL] [Abstract][Full Text] [Related]
55. Bone marrow transplantation in 46 pediatric patients with non-Hodgkin's lymphoma. Spanish Working Party for Bone Marrow Transplantation in Children.
Bureo E; Ortega JJ; Muñoz A; Cubells J; Madero L; Verdaguer A; Baro J; Olivé T; Maldonado MS; Pardo N
Bone Marrow Transplant; 1995 Mar; 15(3):353-9. PubMed ID: 7599558
[TBL] [Abstract][Full Text] [Related]
56. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
57. Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission. Newcastle and Northern Lymphoma Group.
Jackson GH; Lennard AL; Taylor PR; Carey P; Angus B; Lucraft H; Evans RG; Proctor SJ
Br J Cancer; 1994 Sep; 70(3):501-5. PubMed ID: 7521662
[TBL] [Abstract][Full Text] [Related]
58. High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
Shim BY; Lee MA; Byun JH; Roh SY; Song CW; Park JN; Lee JW; Min WS; Hong YS; Kim CC
Korean J Intern Med; 2004 Jun; 19(2):114-20. PubMed ID: 15366643
[TBL] [Abstract][Full Text] [Related]
59. Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma.
Hardingham JE; Kotasek D; Sage RE; Gooley LT; Mi JX; Dobrovic A; Norman JE; Bolton AE; Dale BM
J Clin Oncol; 1995 May; 13(5):1073-9. PubMed ID: 7738613
[TBL] [Abstract][Full Text] [Related]
60. Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: a Pediatric Oncology Group Study.
Crist WM; Shuster JJ; Falletta J; Pullen DJ; Berard CW; Vietti TJ; Alvarado CS; Roper MA; Prasthofer E; Grossi CE
Blood; 1988 Dec; 72(6):1891-7. PubMed ID: 3058229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
